Creation
Draft
Initial
Detailed
Accepted
Adoption
Idea Description
Supplementary Information
Innovation 'Elevator Pitch':
Watson for Genomics provides peer-reviewed, molecular evidence to help oncologists create personalized treatment strategies for patients based on results from genetic testing of tumour tissue.
Overview of Innovation:
Watson for Genomics analyses and categorizes genetic alterations that are related to cancer progression and provides a list of potential therapeutic options that target each alteration. The interpretation is done within minutes, and a comprehensive report is generated. The summary page of the report lists all the critical genetic alterations that were identified in the analysis and associates each with therapeutic options. Levels of evidence, extracted from relevant literature are provided to show the strength of the evidence.
Watson for Genomics presents findings with evidence via hyperlinks to sources for easy drill down. The drug report section provides details of identified drugs with overview, rationale for the association and level of evidence, as well as recruiting clinical trials.
The molecular profile interpretation provides in depth detail of the known genetic alterations found in the tumour sample. For each mutation, molecular and scientific evidence explaining the pathologic relevance of the alteration is provided. The diagram offers easy viewing of mutations with chromosomal location.
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
Similar Content3
Innovation 'Elevator Pitch':
Heart DNA is a genetic testing kit for patients at increased risk of developing atrial fibrillation and other cardiovascular diseases, the results are reviewed and assessed by a consultant who is well informed about the patient’s medical history.
Overview of Innovation:
“Heart DNA” is a genetic testing service for patients at increased risk of developing cardiovascular diseases and for cardiologists and genetic counseling officers/geneticists who would want to work with us in delivering this service to the public.

We are partnering with healthcare professionals who will review (online) the genotyping reports coming from our well established partner lab and will be giving their health assessment based on both: the patient’s health profile/medical record, which our users will be asked to fill in early on our website, and on the genetic predispositions that may be found in the patients DNA. In esssence, our consultants will be able to give an informed screening assessment that covers: the detection of inherited conditions and an assessment to the patients’ response to certain drugs that may well be administered to treat CVDs.

Heart DNA is a simple saliva-based test that is supported by scientifically validated research and an extensive amount of studies. Heart DNA analyses the patient’s unique genetic markers, which influence a broad range of heart-related conditions, our gene panel list consistc of 96 markers that cover: Atrial Fibrillation, Coronary Artery Disease, Myocardial Infraction, Cholesterol levels, and risks for hypertension. It can also help identify a patient’s propensity for increased risk towards certain heart medications, eight classes of drugs that affect the cardiovascular system are examined; anti-platelets, anti-coagulants, statins, stimulants, beta-blockers, ACE inhibitors, calcium channel blockers and hormone therapies.

Our test provides information that allows Doctors to;
1. Monitor a patient’s specific health conditions thoroughly.
2. Prescribe a more optimal medication and dosage for a patient.
3. Suggest early lifestyle and diet interventions to help combat and prevent certain heart conditions.

Overall, the aim is to enable doctors and patients to bridge the gap in genetic information that has proved over an extensive amount of studies and research to be pivotal in the design of better prevention and treatments regimens. Our focus is to cause a change in the architecture of complex care routines that would address the challenges of working at scale, and which can capitalize on the associated opportunities that we will enable by striking business partnerships with medical consultants to create and deliver a distinctive competitive advantage over all competing genetic testing companies. 
Stage of Development:
Trial stage - Trial stage to prove that the idea actually works as intended
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Advanced diagnostics, genomics and precision medicine / Wellness and prevention of illness / Digital health / Patient and medicines safety / Person centred care
Benefit to NHS:
DNA testing is not available at the point of care, regardless of its imperative potential to mitigate treatment regimens and enhance disease prevention pathways. Moreover, once an individual is diagnosed as having a cardiovascular condition, the challenge exist in prescribing the right medication at the right dose in the right time.
Tools promoting optimal direction for healthcare service and moving patients towards the digital space will be hugely disruptive in a market where faster processes and cheaper costs are imperative to its evolution. Products that can enhance the working process inside GPs offices and provide more rapid, reliable and robust diagnosis decisions within primary care, that could enhance workflow for healthcare professionals, assisting earlier triage and potentially redesigning GP care pathways; such products have the potential to save the healthcare and biotech industries over £1bn every year, just in labour time. 

The current pathway to obtain a genetic test for a single cardiac condition through the NHS is lengthy, complex, costy and is not accessible for everyone; with multiple visits and referrals to see healthcare specialsits (Annex; Figure 1). 
Our system workflow has been designed to empower patients within an innovative framework, that ensures having a certified partner cardiologist assessing their health condition before a patient can receive his/her genotyping results. It will also ensure that patients and doctors have an easy access for booking appointments to follow up, when the need is present. Our comprehensive service will cut down the turn around time from several months to 2 weeks with as little steps as the figure shows (Annex; Figure 2). 

Moreover, our database will later provide an electronic medical record through which other healthcare consultants can opt to review when they need to access the patient’s genotype before prescribing a certain drug at any stage of the patient’s life. Thus, cutting down the path of trial and error before the the right medication is prescribed to the patient. 

Early screening for genetic predispositions and having an early risk assessment for patients who may develop Arterial Fibrillation or any other CVD will significantly allow the NHS mitigate prevention regimen for the general public before they become patients. Thus, signinficantly reducing the £15bn bill of CVDs every year (BHF stats 2015).

 
Initial Review Rating
4.20 (1 ratings)
Benefit to WM population:
The major risk factor associated with Atrial Fibrillation and all other CVDs is having a family history with the disease. By family history we are referring to the genes that have passed from the parents to their offspring, which (if found to be mutated as well) can increase the risks of that individual developing the same disease. 
While it is well accepted that such risk factor could not be changed or adjusted (at least for the time being), hence the term "non-modifiable" risk factor, it is also accepted that if such risk is detected then the patient would be better positioned to manage the other "modifiable" risk factors early on, which can significantly change the course of the patient's life and the development course of his/her inherited condition. 

We believe that well informed and educated individuals about their risk factors will allow them take better decisions and have more enlightened judgments when it comes to managing their risk factors and altering their lifestyle and daily habits. Modifiable factor like quite smoking, being fit, eating healthy and managing diabetes, obesity and cholesterol levels, are all found to be imperative in managing AF and other CVDs from an early stage, the earlier the intervention, the better the outcome. 

Moreover, we believe the greatest benefit to the WM population will come at a later stage through our Data Bank which will provide the perfect reference tool to better direct prevention and treatment regimens withihn the WM population, risk factors such as race, age and sex will all be considered in the future direction towards an advanced and precise person-centerd system.



 
Current and planned activity: 
Business partnerships have all been established for the development and delivery of our product/service. Funding is currenly sought to finance our outsourcing agreements:
  • Genotyping analysis will be conducted at a well established genotyping lab in the UK.
  • Our saliva collection kits will be outsourced from a supplier in the UK. 
  • Our service content is all in place and the gene panel list has been put together through an extensive amount of well researched and accredited reference genetic testing studies, the online platform will be developed by website developement agency in Birmingham.
  • Our box and packaging have been designed and the order is to be placed.
  • An initial agreement has been established with a reputable cardiologist consultant to review the patients results and put his recommendations to each genotyping report being assessed.
  • A pilot study is currently being designed by our Medical and Research Officers (both are GPs at the QE hospital). 


 
What is the intellectual property status of your innovation?:
The company will be developing additional patents and intellectual property related to response and side effect prediction for further treatments of hypertension and other Cardiovascular disorders through its DTC kits and the databank that it will generate from its lab based genotyping services. These will be offered to the BHF and all other concerned research groups in the field of Cardiac Health.

In terms of our regulatory path, there are no specific regulations outside consumer protection, data storage, and for storing biological samples “saliva” we will apply control regs that deal directly with this. 
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
1 year
Ease of scalability: 
Simple
Regional Scalability:
Please refer to our commercial information section (Business Strategy)
Measures:
​We are here to help; we believe that we have a relevant and compelling solution that (if adopted) can save lives and enhance the prevention and treatment regimens for patients with cardiovascular conditions.
We will measure our performance based on the value that we are delivering. Hence, by the end of year one we are looking to exceed the 1000 kits sale and have a strong clinical data that would support our proposition, in regards to giving patients better options to mitigate their risk factors and to healthcare professionals to administer drugs that are better suited for certain subpopulations; based on genetic makeup and the health profile "environmental factors" for each individual patient.
These assessments will be made through our end of year statistical study that we will run on all the patients whom we have tested. 
Adoption target:
The adoption target is to demonstrate a successful, valuable and cost efficient systematic framework that would address the core objectives of the NHS Sustainability and Transformation Plans in drving a genuine chnage to patients experience and health outcomes of the longer term.
Read more
Hide details
Innovation 'Elevator Pitch':

Heart DNA is a genetic testing kit for patients at increased risk of developing atrial fibrillation and other cardiovascular diseases, the results are reviewed and assessed by a consultant who is well informed about the patient’s medical history.
Overview of Innovation:
“Heart DNA” is a genetic testing service for patients at increased risk of developing cardiovascular diseases and for cardiologists and genetic counseling officers/geneticists who would want to work with us in delivering this service to the public.

We are partnering with healthcare professionals who will review (online) the genotyping reports coming from our well established partner lab and will be giving their health assessment based on both: the patient’s health profile/medical record, which our users will be asked to fill in early on our website, and on the genetic predispositions that may be found in the patients DNA. In esssence, our consultants will be able to give an informed screening assessment that covers: the detection of inherited conditions and an assessment to the patients’ response to certain drugs that may well be administered to treat CVDs.

Heart DNA is a simple saliva-based test that is supported by scientifically validated research and an extensive amount of studies. Heart DNA analyses the patient’s unique genetic markers, which influence a broad range of heart-related conditions, our gene panel list consistc of 96 markers that cover: Atrial Fibrillation, Coronary Artery Disease, Myocardial Infraction, Cholesterol levels, and risks for hypertension. It can also help identify a patient’s propensity for increased risk towards certain heart medications, eight classes of drugs that affect the cardiovascular system are examined; anti-platelets, anti-coagulants, statins, stimulants, beta-blockers, ACE inhibitors, calcium channel blockers and hormone therapies.

Our test provides information that allows Doctors to;
1. Monitor a patient’s specific health conditions thoroughly.
2. Prescribe a more optimal medication and dosage for a patient.
3. Suggest early lifestyle and diet interventions to help combat and prevent certain heart conditions.

Overall, the aim is to enable doctors and patients to bridge the gap in genetic information that has proved over an extensive amount of studies and research to be pivotal in the design of better prevention and treatments regimens. Our focus is to cause a change in the architecture of complex care routines that would address the challenges of working at scale, and which can capitalize on the associated opportunities that we will enable by striking business partnerships with medical consultants to create and deliver a distinctive competitive advantage over all competing genetic testing companies.
Stage of Development:
Trial stage - Trial stage to prove that the idea actually works as intended
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Advanced diagnostics, genomics and precision medicine / Wellness and prevention of illness / Education, training and future workforce / Wealth creation / Digital health / Innovation and adoption / Patient and medicines safety / Person centred care
Benefit to NHS:
DNA testing is not available at the point of care, regardless of its imperative potential to mitigate treatment regimens and enhance disease prevention pathways. Moreover, once an individual is diagnosed as having a cardiovascular condition, the challenge exist in prescribing the right medication at the right dose in the right time.
Tools promoting optimal direction for healthcare service and moving patients towards the digital space will be hugely disruptive in a market where faster processes and cheaper costs are imperative to its evolution. Products that can enhance the working process inside GPs offices and provide more rapid, reliable and robust diagnosis decisions within primary care, that could enhance workflow for healthcare professionals, assisting earlier triage and potentially redesigning GP care pathways; such products have the potential to save the healthcare and biotech industries over £1bn every year, just in labour time. 

The current pathway to obtain a genetic test for a single cardiac condition through the NHS is lengthy, complex, costy and is not accessible for everyone; with multiple visits and referrals to see healthcare specialsits (Annex; Figure 1). 

Our system workflow has been designed to empower patients within an innovative framework, that ensures having a certified partner cardiologist assessing their health condition before a patient can receive his/her genotyping results. It will also ensure that patients and doctors have an easy access for booking appointments to follow up, when the need is present. Our comprehensive service will cut down the turn around time from several months to 2 weeks with as little steps as the figure shows (Annex; Figure 2). 

Moreover, our database will later provide an electronic medical record through which other healthcare consultants can opt to review when they need to access the patient’s genotype before prescribing a certain drug at any stage of the patient’s life. Thus, cutting down the path of trial and error before the the right medication is prescribed to the patient. 

Early screening for genetic predispositions and having an early risk assessment for patients who may develop Atrial Fibrillation or any other CVD will significantly allow the NHS enhance its' treatment regimen for the general public and prevent high risk individuals from becoming patients. Thus, causing a substantial reduction in the £15bn bill of CVDs every year (BHF stats 2015).
Online Discussion Rating
6.00 (1 ratings)
Initial Review Rating
4.60 (1 ratings)
Benefit to WM population:
The major risk factor associated with Atrial Fibrillation and all other CVDs is having a family history with the disease. By family history we are referring to the genes that have passed from the parents to their offspring, which (if found to be mutated as well) can increase the risks of that individual developing the same disease. 

While it is well accepted that such risk factor could not be changed or adjusted (at least for the time being), hence the term "non-modifiable" risk factor, it is also accepted that if such risk is detected then the patient would be better positioned to manage the other "modifiable" risk factors early on, which can significantly change the course of the patient's life and the development course of his/her inherited condition. 

We believe that well informed and educated individuals about their risk factors will allow them take better decisions and have more enlightened judgments when it comes to managing their risks and altering their lifestyle and daily habits. Modifiable factor like quite smoking, being fit, eating healthy and managing diabetes, obesity and cholesterol levels, are all found to be imperative in managing AF and other CVDs from an early stage; the earlier the intervention, the better the outcome. 

Moreover, we believe the greatest benefit to the WM population will come at a later stage through our Data Bank which will provide the perfect reference tool to better direct prevention and treatment regimens withihn the WM population, risk factors such as race, age and sex will all be considered in the future direction of our research through our advanced and precise person-centerd system.
 
Current and planned activity: 
Business partnerships have all been established for the development and delivery of our product/service. Funding is currenly sought to finance our outsourcing agreements:
  • Genotyping analysis will be conducted at a well established genotyping lab in the UK.
  • Our saliva collection kits will be outsourced from a supplier in the UK. 
  • Our service content is all in place and the gene panel list has been put together through an extensive amount of well researched and accredited reference genetic testing studies, the online platform will be developed by website developement agency in Birmingham.
  • Our box and packaging have been designed and the order is to be placed.
  • An initial agreement has been established with a reputable cardiologist consultant to review the patients results and put his recommendations to each genotyping report being assessed.
  • A pilot study is currently being desinged by our Medical and Research Officers (both are GPs at the QE hospital).
What is the intellectual property status of your innovation?:
The company will be developing additional patents and intellectual property related to response and side effect prediction for further treatments of hypertension and other Cardiovascular disorders through its DTC kits and the databank that it will generate from its lab based genotyping services. These will be offered to the BHF and all other concerned research groups in the field of Cardiac Health.

In terms of our regulatory path, there are no specific regulations outside consumer protection, data storage, and for storing biological samples “saliva” we will apply control regs that deal directly with this. 
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
1 year
Ease of scalability: 
Simple
Regional Scalability:
Please refer to our commercial information section (Business Strategy)
Measures:
We are here to help; we believe that we have a relevant and compelling solution that (if adopted) can save lives and enhance the prevention and treatment regimens for patients with cardiovascular conditions.
We will measure our performance based on the value that we are delivering. Hence, by the end of year one we are looking to exceed the 1000 kits sale and have a strong clinical data that would support our proposition, in regards to giving patients better options to mitigate their risk factors and to healthcare professionals to administer drugs that are better suited for certain subpopulations; based on genetic makeup and the health profile "environmental factors" for each individual patient.
These assessments will be made through our end of year statistical study that we will run on all patients whom we have tested. 
Adoption target:
The adoption target is to demonstrate a successful, valuable and cost efficient systematic framework that would address the core objectives of the NHS Sustainability and Transformation Plans in drving a genuine chnage to patients experience and health outcomes of the longer term. 
 
Read more
Hide details
Overview summary:
The West Midlands GMC (WMGMC) is the largest GMC, working with all 18 acute trusts in the region to underpin the delivery of the project. The WMGMC Education Team has developed a suite of educational programmes to ensure the region’s current and future workforce is equipped to understand how genomics medicine might impact on their role.
Challenge identified and actions taken :
The WMGMC Education Team has developed a suite of educational programmes to ensure the region’s current and future workforce is equipped to understand how genomics medicine might impact on their role. 
  • Developing and delivering consent training for healthcare staff across the region
  • The development of National Consent and Recruitment ‘Train the Trainer’ days for staff from all GMCs, using a blended learning approach Partnership working with the University of Birmingham, which offers an MSc in Genomic Medicine and associated Continuing Professional Development (CPD) modules
  • Delivering a Genomics Access Course to provide intermediate genomics training and support applications to the MSc in Genomic Medicine
  • Providing work experience opportunities in genetic counselling and genomics for GCSE and A-level students, in partnership with HealthTec
  • Contributing to the development of Advanced Clinical Practitioner roles in genomics
  • Working closely with the Genomics Ambassadors to promote education and training across the 18 trusts
  • Engaging with primary care.
  • Developing a system-wide training needs analysis in line with national requirements
Impacts / outcomes: 
The immediate training priority for the West Midlands was to train sufficient numbers of health care professionals, with some existing genetics knowledge, to recruit and consent patients across a number of local delivery partners (LDPs) in line with the phased roll out of the 100,000 Genomes project. A further learning need was identified whilst working with the University of Birmingham (UoB), the local provider of the MSc in Genomic Medicine;  non-medical health care professionals were dissuaded from applying for both CPD modules and the MSc due to insufficient knowledge in basic genetics science. 
 
The West Midlands working with UoB developed an Access Course designed to educate non –medical healthcare professionals who had little knowledge of genetics or genomics and to support them in successfully meeting the entry requirements for the MSc in Genomics. Other courses provided by the WMGMC included an interactive one-day recruitment and consent programme as well as a blended E-Learning Consent course which built on work from Health Education England (HEE).
A national consent training day was also organised to allow for additional training alongside the blended learning package.
 
The Recruitment and Consent course delivered both centrally and through blended learning has been hugely effective. Locally it enabled individual clinics across 18 LDPs to meet recruitment targets across cancer and rare diseases. Furthermore, these genomics training events are thought to have contributed to interest in and attendance on CPD modules as well as the full MSc in Genomic Medicine at the UoB.
 
The phased roll out of the 100,000 Genomes Project has also been assisted by the three Genomic Ambassadors. As part of a focus on precision medicine the AHSN sought to fund these 3 innovative posts known as Genomic Ambassadors. In the early days the role largely comprised of engagement of various healthcare professionals, coordinating teams ahead of going live to recruitment as well as training staff to consent patients. The genomics ambassadors regularly take part in regional and national events to raise awareness for not only the 100,000 Genomes Project but also personalised medicine, an important aspect which has also developed their ability to educate groups of people including nurses, scientists and students.
 
As well as events focussed on workforce training the Education Team have helped with activities to ensure the future workforce is aware of genomics. This includes enabling work experience opportunities for  school, college and university students ensuring the next generation of scientists, nurses and doctors receive vital experience within the genomics and genetics field.
 
The WMGMC has also worked closely with the national Genomics Education Programme team to ensure national requests are fulfilled. This has included producing a training needs analysis questionnaire to highlight the needs of different staff groups. Each GMC was asked to produce a questionnaire suited to their workforce with the focus of the WMGMC being Healthcare scientists. From this a national report is to be produced which will hopefully influence training and education opportunities in genomics that will be available in the future.
Which local or national clinical or policy priorities does this innovation address:
The 100,000 Genomes Project is a national initiative. To help deliver this project Genomics England was established. Two of the four main aims of Genomics England are to bring benefit to patients and set up a genomic medicine service for the NHS and kick start the development of a UK genomics industry. These points in particular highlight the importance of the Genomics Education Programme and the need for the workforce to receive the relevant training and education.
Supporting quote for the innovation from key stakeholders:
“I don’t want it to end, I don’t want to stop learning” ~ Genomics Access Course Participant
 
‘We certainly enjoying running the course and were excited to be able to share our insights into Genomics and the impact of the 100,000 Genomes project to healthcare both now and in the future.  We were pleased meet so many of our colleagues working in and around genomics in the West Midlands and be able to inspire and enthuse them to put their new found knowledge into practice.’

Laura Boyes, Lead Consultant Genetic Counsellor
Plans for the future:
Education in the West Midlands Genomic Medicine Centre continues to be vital. With the return of results from the 100,000 Genomes Project staff will need to be trained to effectively inform patients about the outcome of their genetic testing. Currently the hope is for members of Multi-Disciplinary Teams and leads of the soon to be established Tumour Boards to receive two days of training with the opportunity for further half days of training which will delve into more advanced content.
 
As well as this the Education Team have recently been successful with a bid to HEE for the development of an interactive education and training tool around Genomics aimed at supporting higher education institutes to deliver high quality education to their undergraduates. This will start initially with undergraduate nurses and medical students but will be expanded to support other programmes. The programme will be `train the trainer` style to expand the knowledge base of genomics across undergraduate teachers.
Tips for adoption:
Identify and plan for both immediate and longer term needs with the right stakeholders to ensure that the training offered is delivered at the relevant time and has the right buy in. 
 
Classroom based training in this instance has needed to be followed up to ensure course participants have the confidence to practice. Having on the ground ‘ambassador roles’ has enabled the right level of support to be given locally following formal training and which has been essential.
 
Good Planning!
Contact for further information:
Kirsten Chalk
Education and Engagement Project Officer
2nd Floor Open Plan Office
Institute of Translational Medicine
Heritage Building, QEHB
Mindelsohn Way
B15  2TH
 
0121 371 8161
Read more
Hide details
3
1
Votes
-99999

Created by

Share and Follow